These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 38587585)

  • 1. Distribution of Bevacizumab into the Cerebrospinal Fluid of Children and Adolescents with Recurrent Brain Tumors.
    Minichmayr IK; Knaack U; Gojo J; Senfter D; Haberler C; Azizi AA; Mayr L; Zeitlinger M; Peyrl A
    Paediatr Drugs; 2024 Jul; 26(4):429-440. PubMed ID: 38587585
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I and Biomarker Study of Plerixafor and Bevacizumab in Recurrent High-Grade Glioma.
    Lee EQ; Duda DG; Muzikansky A; Gerstner ER; Kuhn JG; Reardon DA; Nayak L; Norden AD; Doherty L; LaFrankie D; Stefanik J; Vardam T; Smith KH; McCluskey C; Gaffey S; Batchelor TT; Jain RK; Wen PY
    Clin Cancer Res; 2018 Oct; 24(19):4643-4649. PubMed ID: 29941486
    [No Abstract]   [Full Text] [Related]  

  • 3. Differential expression of vascular endothelial growth factor A, its receptors VEGFR-1, -2, and -3 and co-receptors neuropilin-1 and -2 does not predict bevacizumab response in human astrocytomas.
    Baumgarten P; Blank AE; Franz K; Hattingen E; Dunst M; Zeiner P; Hoffmann K; Bähr O; Mäder L; Goeppert B; Machein M; Seifert V; Steinbach JP; Plate KH; Harter PN; Mittelbronn M
    Neuro Oncol; 2016 Feb; 18(2):173-83. PubMed ID: 26627848
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bevacizumab dosing strategy in paediatric cancer patients based on population pharmacokinetic analysis with external validation.
    Han K; Peyret T; Quartino A; Gosselin NH; Gururangan S; Casanova M; Merks JH; Massimino M; Grill J; Daw NC; Navid F; Jin J; Allison DE
    Br J Clin Pharmacol; 2016 Jan; 81(1):148-60. PubMed ID: 26345283
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Compassionate use of bevacizumab (Avastin) in children and young adults with refractory or recurrent solid tumors.
    Benesch M; Windelberg M; Sauseng W; Witt V; Fleischhack G; Lackner H; Gadner H; Bode U; Urban C
    Ann Oncol; 2008 Apr; 19(4):807-13. PubMed ID: 18056650
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Systemic bevacizumab as adjuvant therapy for recurrent respiratory papillomatosis in children: A series of three pediatric cases and literature review.
    Enrique OH; Eloy SH; Adrian TP; Perla V
    Am J Otolaryngol; 2021; 42(5):103126. PubMed ID: 34175693
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Single-agent bevacizumab in the treatment of recurrent or refractory pediatric low-grade glioma: A single institutional experience.
    Gorsi HS; Khanna PC; Tumblin M; Yeh-Nayre L; Milburn M; Elster JD; Crawford JR
    Pediatr Blood Cancer; 2018 Sep; 65(9):e27234. PubMed ID: 29750399
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase I, randomized, single-dose pharmacokinetic study comparing sb8 (bevacizumab biosimilar) with reference bevacizumab in healthy volunteers.
    Shin D; Lee YJ; Choi J; Lee D; Park M; Petkova M
    Cancer Chemother Pharmacol; 2020 Oct; 86(4):567-575. PubMed ID: 32949267
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rechallenging Recurrent Glioblastoma with Intra-Arterial Bevacizumab with Blood Brain-Barrier Disruption Results in Radiographic Response.
    Faltings L; Kulason KO; Patel NV; Wong T; Fralin S; Li M; Schneider JR; Filippi CG; Langer DJ; Ortiz R; Boockvar JA
    World Neurosurg; 2019 Nov; 131():234-241. PubMed ID: 31351210
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I expansion cohort to evaluate the combination of bevacizumab, sorafenib and low-dose cyclophosphamide in children and young adults with refractory or recurrent solid tumours.
    Federico SM; Caldwell KJ; McCarville MB; Daryani VM; Stewart CF; Mao S; Wu J; Davidoff AM; Santana VM; Furman WL; Pappo AS; Navid F
    Eur J Cancer; 2020 Jun; 132():35-42. PubMed ID: 32325418
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase 1 dose-escalation study of the antiplacental growth factor monoclonal antibody RO5323441 combined with bevacizumab in patients with recurrent glioblastoma.
    Lassen U; Chinot OL; McBain C; Mau-Sørensen M; Larsen VA; Barrie M; Roth P; Krieter O; Wang K; Habben K; Tessier J; Lahr A; Weller M
    Neuro Oncol; 2015 Jul; 17(7):1007-15. PubMed ID: 25665807
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A comparative pharmacokinetic study of DRL_BZ, a candidate biosimilar of bevacizumab, with Avastin
    Wynne C; Schwabe C; Batra SS; Lopez-Lazaro L; Kankanwadi S
    Br J Clin Pharmacol; 2018 Oct; 84(10):2352-2364. PubMed ID: 29943831
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improvement of health related quality of life in patients with recurrent glioma treated with bevacizumab plus daily temozolomide as the salvage therapy.
    Liu Y; Feng F; Ji P; Liu B; Ge S; Yang C; Lou M; Liu J; Li B; Gao G; Qu Y; Wang L
    Clin Neurol Neurosurg; 2018 Jun; 169():64-70. PubMed ID: 29631109
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacogenetics in Model-Based Optimization of Bevacizumab Therapy for Metastatic Colorectal Cancer.
    Papachristos A; Karatza E; Kalofonos H; Sivolapenko G
    Int J Mol Sci; 2020 May; 21(11):. PubMed ID: 32466535
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study.
    Lee MS; Ryoo BY; Hsu CH; Numata K; Stein S; Verret W; Hack SP; Spahn J; Liu B; Abdullah H; Wang Y; He AR; Lee KH;
    Lancet Oncol; 2020 Jun; 21(6):808-820. PubMed ID: 32502443
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antiangiogenic therapy for high-grade glioma.
    Khasraw M; Ameratunga MS; Grant R; Wheeler H; Pavlakis N
    Cochrane Database Syst Rev; 2014 Sep; (9):CD008218. PubMed ID: 25242542
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Treatment of recurrent glioblastoma with single-agent bevacizumab].
    Sinkó D; Nemeskéri C
    Orv Hetil; 2016 Mar; 157(13):500-3. PubMed ID: 26996897
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeted therapy with bevacizumab and erlotinib tailored to the molecular profile of patients with recurrent glioblastoma. Preliminary experience.
    D'Alessandris QG; Montano N; Cenci T; Martini M; Lauretti L; Bianchi F; Larocca LM; Maira G; Fernandez E; Pallini R
    Acta Neurochir (Wien); 2013 Jan; 155(1):33-40. PubMed ID: 23132371
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metronomic chemotherapy with daily, oral etoposide plus bevacizumab for recurrent malignant glioma: a phase II study.
    Reardon DA; Desjardins A; Vredenburgh JJ; Gururangan S; Sampson JH; Sathornsumetee S; McLendon RE; Herndon JE; Marcello JE; Norfleet J; Friedman AH; Bigner DD; Friedman HS
    Br J Cancer; 2009 Dec; 101(12):1986-94. PubMed ID: 19920819
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CD44 expression in the tumor periphery predicts the responsiveness to bevacizumab in the treatment of recurrent glioblastoma.
    Nishikawa M; Inoue A; Ohnishi T; Yano H; Kanemura Y; Kohno S; Ohue S; Ozaki S; Matsumoto S; Suehiro S; Nakamura Y; Shigekawa S; Watanabe H; Kitazawa R; Tanaka J; Kunieda T
    Cancer Med; 2021 Mar; 10(6):2013-2025. PubMed ID: 33543833
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.